Teva’s Ajovy hits endpoint in Chinese Phase III Trial for Migraine Prevention

Teva Pharmaceuticals has released encouraging results from a Phase III trial assessing Ajovy (fremanezumab) for migraine prevention in Chinese adult patients.

Ajovy, already approved in the US and Europe for adult migraine prevention, received regulatory clearance from the US FDA and the European Medicines Agency in 2018 and 2019 respectively.

The recent Phase III study involved 365 Chinese patients with episodic or chronic migraines. Half of them received subcutaneous injections of Ajovy at either 225mg once monthly for three months or 675mg once quarterly, while the other half received a placebo. Teva reported meeting the trial's primary endpoint as well as all secondary endpoints related to efficacy and safety. Patients treated with Ajovy experienced a decrease in monthly migraine days, showing promising efficacy within the initial three months. Teva, headquartered in Israel, noted a favourable safety profile.

Ajovy, a monoclonal antibody, functions by binding to calcitonin gene-related peptide (CGRP), a neurotransmitter implicated in migraine development, thereby inhibiting its interaction with target cells.